Iain Baird

Iain Baird is co-founder of Arranta Bio, which was established in May 2019.

Mr. Baird has worked with the founders/CEOs of 6 companies over the last 10 years starting companies developing new biological pharmaceutical products and CDMO’s providing services to the sector, including OSO BioPharmaceuticals Manufacturing, CANbridge Life Sciences, Gallus Biopharmaceuticals, and Brammer Bio.

Prior to that Mr. Baird worked for 20 years, in the pharmaceutical and chemical industries. He started work for ICI which later became Zeneca and then AstraZeneca. An engineer by discipline he initially designed and project managed the building of pharmaceutical facilities before moving into operational management running multiple production facilities in the United Kingdom. Since 2002 he has worked in the USA and was part of the leadership team that established the Avecia Oligonucleotides business as a CMO, taking a small team of researchers and growing it into an FDA approved manufacturing site with 150 employees. In 2006 Mr. Baird was one of the principles that established Avecia Vaccines in which he led the Chemistry Manufacturing and Control groups in the development of vaccines against anthrax and plague.

Since 2010 Iain has been an independent consultant assisting clients in the development of their clinical products and has been involved in filing 16 IND’s, 3 successful BLA applications and 3 successful NDA applications as well as remediating a product placed on CMC hold by the FDA. Iain has supported clients through numerous FDA, EMA and international regulatory inspections, preparing them for the inspections, supporting them during the inspections and in their successful responses.

Mr. Baird holds a BEng in mechanical and electrical engineering from Robert Gordons University.